Dr. Reddy’s Laboratories announced the launch of Paricalcitol Injection, the generic version of AbbVie‘s Zemplar

Zemplar Injection, a vitamin D analog, is indicated for secondary hyperparathyroidism due to chronic renal failure. The biological effects of paricalcitol are mediated through binding of the vitamin D receptor, which results in the selective activation of the vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting parathyroid hormone synthesis and secretion. 

Related Articles

Paricalcitol Injection is available as 2mcg, 5mcg, and 10mcg strengths. 

For more information call (866) 733-3952 or visit DrReddys.com.